Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Gastric Modulator (TANTALUS® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients - a Randomized Control Trial

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Chinese University of Hong Kong.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Metacure
Information provided by:
Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT00975533
First received: September 10, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted

September 10, 2009
September 10, 2009
October 2009
July 2011   (final data collection date for primary outcome measure)
  • changes in body weight before and after interventions at 6 and 12 months [ Time Frame: 6 months and 1 year ] [ Designated as safety issue: No ]
  • changes in HbA1c before and after interventions [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]
  • frequency of hypoglycaemia [ Time Frame: 6 month and 1 year ] [ Designated as safety issue: Yes ]
  • dichotomous composite end point assessing the proportion of patients meeting all of the following prespecified criteria defined as: 1. HbA1c ≤7.0% or an HbA1c reduction from baseline ≥0.5% 2. no weight gain 3. no severe hypoglycaemia [ Time Frame: 6 and 12 months ] [ Designated as safety issue: Yes ]
  • composite quantitative score calculate from the results of glycemic control, weight response and degree of hypoglycemia [ Time Frame: 6 month and 1 year ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
  • waist circumferences [ Time Frame: 6 month and 1 year ] [ Designated as safety issue: No ]
  • insulin secretory responses (as measured by the standard meal test) [ Time Frame: 6 month and 1 year ] [ Designated as safety issue: No ]
  • Hormonal profiles (including gut hormones) [ Time Frame: 6 months and 1 year ] [ Designated as safety issue: No ]
  • a. eating behavior, satiety and quality of life as measured by the Food Frequency Questionnaire, Visual Analogue Rating Scale To Assess Satiety, EDE, SF-36 and GIQOL questionnaires [ Time Frame: 6 month and 1 year ] [ Designated as safety issue: No ]
  • resting energy expenditure as monitored by indirect calorimetry (MedGem). [ Time Frame: 6 month and 1 year ] [ Designated as safety issue: No ]
  • radiological assessment (ultrasound scan and densitometry to measure mesenteric and total body fat respectively) [ Time Frame: 6 months and 1 year ] [ Designated as safety issue: No ]
  • differences in insulin requirement [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Gastric Modulator (TANTALUS® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients - a Randomized Control Trial
A Randomized Study to Evaluate the Efficacy and Acceptability of Laparoscopic Placement of Gastric Modulator (TANTALUS® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients Sub-optimally Controlled With Oral Anti-diabetic Agents.

This study aims to analyze the pre- and post-operative clinical, hormonal and biochemical changes in moderately obese type 2 diabetic patients who are sub-optimally controlled on at least 2 anti-diabetic agents. Study participants will either receive implantation of the gastric contraction modulator or conventional treatment with insulin therapy.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
  • Device: Tantalus
    The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
  • Drug: Insulin
    Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
  • Experimental: Tantalus
    The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM. The device is intended to improve glycemic control and induce weight loss.
    Intervention: Device: Tantalus
  • Active Comparator: Control
    Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
    Intervention: Drug: Insulin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
24
October 2011
July 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Able to provide written informed consent
  • Adult patients aged between 18 and 60 years (inclusive)
  • Male or female of Chinese ethnicity
  • Type 2 diabetes mellitus with disease duration of greater than 2 and less than 10 years
  • severe obesity, includes BMI 25 to 27.5 kg/m and central obesity defined by waist circumference greater than 90 cm in women and greater than 95 in men, or BMI greater than 27.5 to less than 35 kg/m
  • HbA1c greater than or equals to 7.5% but less than 10% despite treated with maximum dose or maximally tolerated dose of 2 anti-diabetic drugs (OAD) with good drug compliance

Exclusion Criteria:

  • On anti-obesity drugs
  • On insulin treatment at the time of the recruitment
  • On glitazone or incretins (dipeptidyl peptidase-4 inhibitor or glucagons-like peptide-1) treatment
  • On any implantable device including cardiac pacing
  • Anticipated to have MRI examinations
  • Fasting C-peptide level less than 0.5g/L
  • Renal impairment (defined as serum creatinine greater than 150mol/L and/or estimated glomerular filtration rate less than 60 mL/min/1.73m)
  • Significant liver impairment (ALT more than 3 times upper limit of normal range)
  • Active malignant disease. Patients with malignant disease who have been disease-free for at least 5 years are eligible
  • Active infection
  • Active and uncontrolled thyroid diseases
  • Childbearing age female patients without reliable contraceptive methods
  • Life expectancy less than 12 months
  • Administration of another investigational drugs or procedures within 4 weeks before screening
  • Any medical illness or condition as judged by the investigators as ineligible to participate the study
  • Special population, e.g. prisoner, mentally disabled, investigators' student or employees
Both
18 Years to 60 Years
No
Contact: Simon KH Wong, MBChB 852-26322627 wongkhmo@cuhk.edu.hk
China
 
NCT00975533
CRE-2008.335
No
Simon Kin-Hung WONG, The Chinese University of Hong Kong
Chinese University of Hong Kong
Metacure
Principal Investigator: Simon KH Wong, MBChB Chinese University of Hong Kong
Chinese University of Hong Kong
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP